Dr. Matthias Liechti

MindMed’s (NASDAQ: MNMD) recurring collaborator, Prof. Dr. Matthias Liechti of the University Hospital Basel (UHB), will lead a novel Phase 1 clinical trial aiming to compare acute responses to R-MDMA, S-MDMA and MDMA in healthy subjects, which is set to begin on Tuesday. The study will...

Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline. The move comes as part of the company’s exclusive collaboration agreement with the University...